Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
AbbVie
Hoffmann-La Roche
Eikon Therapeutics
Regeneron Pharmaceuticals
Canadian Cancer Trials Group
Polaris Group
Fudan University
National Cancer Institute, Naples
Taizhou Hanzhong biomedical co. LTD
Tianjin Medical University Cancer Institute and Hospital
Boehringer Ingelheim
Guangdong Association of Clinical Trials
AIO-Studien-gGmbH
Transgene
National Cancer Institute (NCI)